RAP-219 hits primary endpoint in Phase 2 bipolar mania trial with statistically significant 3.1-point placebo-adjusted ...
AI can generate 100x more drug candidates, but trials still need real patients. The bottleneck has shifted, and most sponsors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results